S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Arsenic trioxide (Primary) ; Daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Tretinoin (Primary)
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Primary endpoint (Mortality rate at 6 weeks) has been met, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Primary endpoint (Continuous complete remission at 3 years) has been met, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology